Skip to main content

Epidemiology, ventilation management, and clinical outcomes in children (PRoVENT-PED): first results from the 10-year, investigator-initiated, international, multicentre, prospective cohort study.

The Lancet. Respiratory medicine2026-05-06PubMed
Total: 77.0Rigor: 8Innovation: 7Journal: 8Clinical: 8

Summary

In a prospective international cohort of 1427 invasively ventilated children across 83 ICUs in 34 countries, PARDS was present in 11% and was most common in preschool-aged children. Overall 28-day ICU mortality was 14%, with higher mortality in PARDS (27%) than non-PARDS (12%), and ventilator management varied by age and PARDS status with younger age and PARDS associated with exposure to higher airway pressures.

Key Findings

  • Prospective cohort enrolled 1427 children across 83 ICUs in 34 countries.
  • PARDS was identified in 164 children (11%), most frequent in preschool-aged patients.
  • 28-day ICU mortality was 14% overall, lowest in neonates (3%) and higher in PARDS than non-PARDS (27% vs 12%).
  • Ventilation practices varied by age and PARDS status; younger age and PARDS were associated with exposure to high airway pressures.
  • Study registered at ClinicalTrials.gov (NCT06220825).

Clinical Implications

Findings support age-tailored ventilation strategies in children and heightened attention to airway pressure exposure in PARDS. The mortality patterns provide contemporary benchmarks to inform quality improvement and trial design.

Why It Matters

This large, registered, prospective cohort fills a major evidence gap in pediatric ventilation by mapping age-specific practices and outcomes worldwide and quantifying mortality differences associated with PARDS.

Limitations

  • Observational design limits causal inference and residual confounding may persist
  • Abstract does not provide complete details on associations of specific ventilator variables with outcomes

Future Directions

Define age-specific ventilation targets (e.g., airway pressure thresholds) in interventional trials and explore long-term outcomes beyond 28 days.

Study Information

Study Type
Cohort
Research Domain
Prognosis
Evidence Level
III - Prospective, multicentre observational cohort study without randomization
Study Design
OTHER